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IgG4-related Hashimoto’s 
thyroiditis – A new variant of 
a well known disease
Tireoidite de Hashimoto associada a IgG4 – Uma 
nova variante de uma doença bem conhecida
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SUMMARY
Hashimoto’s thyroiditis (HT) has been characterized for many years as a well-defined clinicopatholo-
gic entity, but is now considered a heterogeneous disease. IgG4-related HT is a new subtype charac-
terized by thyroid inflammation rich in IgG4-positive plasma cells and marked fibrosis. It may be part 
of the systemic IgG4-related disease. We report a case of a 56-year-old Portuguese man who presen-
ted with a one-month history of progressive neck swelling and dysphagia. Laboratory testing revea-
led increased inflammatory parameters, subclinical hypothyroidism and very high levels of thyroid 
autoantibodies. Cervical ultrasound (US) demonstrated an enlarged and heterogeneous thyroid 
gland and two hypoechoic nodules. US-guided fine needle aspiration cytology was consistent with 
lymphocytic thyroiditis. The patient was submitted to total thyroidectomy and microscopic exami-
nation identified typical findings of HT, marked fibrosis limited within the thyroid capsule and lym-
phoplasmacytic infiltration, with > 50 IgG4-positive plasma cells per high-power field and an IgG4/
IgG ratio of > 40%. After surgery, serum IgG4 concentration was high-normal. Symptoms relief and 
reduction in laboratory inflammatory parameters were noticed. Thyroid function is controlled with 
levothyroxine. To our knowledge we report the first case of IgG4-related HT in a non-Asian patient. 
We also perform a review of the literature regarding IgG4-related disease and IgG4-related HT. Our 
case highlights this new variant of the well known HT, and helps physicians in recognizing its main 
clinical features, allowing for proper diagnosis and treatment. Arq Bras Endocrinol Metab. 2014;58(8):862-8 
SUMÁRIO
A tireoidite de Hashimoto (TH) foi caracterizada durante muitos anos como uma entidade clinicopa-
tológica bem definida, mas é atualmente considerada uma patologia heterogênea. A TH associada 
a IgG4 apresenta-se como um novo subtipo, sendo caracterizada por inflamação da tireoide com 
numerosos plasmócitos IgG4-positivos e fibrose extensa. É possível que pertença ao espectro da 
doença sistêmica associada a IgG4. Relatamos o caso de um homem português de 56 anos que se 
apresentou com aumento progressivo do volume cervical e disfagia, com um mês de evolução. A 
avaliação laboratorial revelou elevação dos parâmetros inflamatórios, hipotireoidismo subclínico e 
níveis muito elevados de autoanticorpos tireoidianos. Por ultrassonografia cervical demonstrou-se 
tireoide aumentada, heterogênea, com dois nódulos hipoecoicos. Foi realizada citologia aspirativa 
com agulha fina guiada por ultrassom, compatível com tireoidite linfocítica. O doente foi submetido 
à tireoidectomia total e o exame histológico revelou achados típicos de TH, extensa fibrose localiza-
da dentro da cápsula tireoidiana e infiltrado linfoplasmocitário, com > 50 plasmócitos IgG4-positi-
vos por campo de grande ampliação e uma relação IgG4/IgG > 40%. Após cirurgia, a concentração 
sérica de IgG4 encontrava-se no limite superior do normal. Ocorreu melhoria sintomática e redução 
dos parâmetros inflamatórios. A função tireoidiana foi controlada com levotiroxina. Relatamos o 
primeiro caso de TH associada a IgG4 num indivíduo não asiático. Além disso, realizamos uma 
revisão da literatura sobre doença associada a IgG4 e TH associada a IgG4. Este caso destaca uma 
nova variante da TH e permite aos médicos reconhecerem suas principais características clínicas, 
proporcionando diagnóstico e tratamento adequados. Arq Bras Endocrinol Metab. 2014;58(8):862-8
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INTRODUCTION
H ashimoto’s thyroiditis (HT) was first reported in 1912 by Hakaru Hashimoto, who described four 
patients with a chronic disorder of the thyroid gland 
(1). It is the most common cause of hypothyroidism in 
areas of the world where dietary iodine is sufficient and 
is defined by the presence of goiter and serum thyroid 
autoantibodies (2). Typical histological features of HT 
include lymphoplasmacytic infiltration, lymphoid folli-
cles with germinal center formation and the presence of 
large follicular cells with abundant granular eosinophilic 
cytoplasm (oxyphilic cells). For many years, it has been 
characterized as a well-defined clinicopathologic entity. 
However, HT is now considered a heterogeneous and 
poorly understood disease, with several subtypes, pre-
sentation forms, pathogenesis and outcomes.
IgG4-related HT is a new subtype, first recognized 
by Li and cols. in 2009 (3) and characterized by thyroid 
inflammation rich in IgG4-positive plasma cells and 
marked fibrosis. It may be part of the systemic IgG4-
related disease. There are few articles about this topic, 
all of them from Japan. 
We report, to our knowledge, the first case of IgG4-
related HT in a non-Asian patient, and perform a re-
view of the related literature.
CASE REPORT
A 56-year-old Portuguese man presented to the out-
patient clinic with a one-month history of progressive 
neck swelling and dysphagia. No symptoms of thyroid 
dysfunction were noticed. His past medical history was 
unremarkable. He had Portuguese descent and no rele-
vant family diseases. The patient had good general con-
dition and nutritional status and presented with diffuse 
neck swelling (Figure 1A). Cervical palpation identified 
an enlarged, hard and painless thyroid gland. He had 
no palpable adenopathies. His respiratory and abdomi-
nal exams were normal. No other changes were found 
on physical examination.
Laboratory testing revealed a normal hemoglobin 
level of 15.1 g/dL (normal, 14-18), a normal white 
blood cell count of 10.4 X 103/µL (normal, 4-11) and 
an elevated platelet count of 521 X 103/µL (normal, 
150-450). Increased erythrocyte sedimentation rate 
(ESR) of 81 mm/h (normal, < 31) and C-reactive 
protein of 8.2 mg/dL (normal, < 1) were found, with 
an elevated thyroid-stimulating hormone (TSH) of 19 
mIU/L (normal, 0.1-4) and a normal free thyroxine 
(FT4) of 0.99 ng/dL (normal, 0.93-1.7). Very high 
thyroid peroxidase and thyroglobulin antibodies were 
noticed, with levels of > 600 IU/mL (normal, < 35) 
and > 4000 IU/mL (normal, < 40), respectively.
Cervical ultrasound (US) demonstrated an en-
larged and heterogeneous thyroid gland, both lobes 
with maximal dimension > 10 cm and two hypoechoic 
nodules with 3.2 and 2.2 cm located on the isthmus 
and right lobe, respectively (Figure 1B). Cervical com-
puted tomography (CT) showed a thyroid gland with 
increased dimensions and a substernal component, pro-
ducing a mass effect on the trachea with tracheal shift 
to the right and slightly reducing its caliber, with no 
visible adenopathies (Figure 2). US-guided fine needle 
aspiration cytology was performed and the material re-
moved from both nodules was consistent with lympho-
cytic thyroiditis.
Figure 1. (A) Initial presentation of the patient with diffuse neck swelling. (B) Cervical ultrasound image showing a hypoechoic nodule with 3.2 cm of 
maximal dimension located on the thyroid isthmus.
A B
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The patient was submitted to total thyroidectomy. 
Due to the size of the gland and the presence of fi-
brosis, the surgical procedure was complex and time-
consuming, with difficulties in mobilizing the thyroid 
gland. Surgeons have identified and preserved the 
recurrent  laryngeal  nerve and the parathyroid glands 
and had no other complications. Macroscopic findings 
showed a thyroid gland with a weight of 284 g (right 
lobe 10 x 6 x 4.5 cm and left lobe 12 x 6 x 6 cm) and 
a hard consistency. Microscopic examination identified 
lymphoplasmacytic infiltration, lymphoid follicles with 
germinal centers, oxyphilic cells, focal squamous meta-
plasia, atrophic follicles and marked fibrosis limited 
within the thyroid capsule. Immunostaining for IgG4 
(mouse monoclonal, HP6025, 1:40; GeneTex, Irvine, 
USA) and IgG (rabbit polyclonal, NCL-IgGp, 1:2500; 
Novocastra, Newcastle, UK) was performed on a Ven-
tana BenchMark ULTRA with Ultra DAB Detection 
Kit. Tonsil tissue served as a positive control. Five high-
power field (HPF) were counted and > 50 IgG4-posi-
tive plasma cells per HPF were found (Figure 3). The 
calculated IgG4/IgG ratio was > 40% (Figure 4).
One month after surgery, serum IgG4 concentra-
tion was high-normal, 187 and 165 mg/dL (normal, 
3-201). Symptoms relief and reduction in laboratory 
inflammatory parameters, with an ESR of 20 mm/h, 
were noticed. Thyroid function is controlled with le-
vothyroxine 137 µg/day (TSH 2.9 mIU/L, FT4 1.2 
ng/dL, thyroid peroxidase antibodies > 600 IU/mL 
and thyroglobulin antibodies > 4000 IU/mL) and the 
patient is normocalcemic and has a normal parathyroid 
hormone level. The remaining basal pituitary function 
is unremarkable, including normal levels of follicle-
stimulating hormone, luteinizing hormone, growth 
hormone, insulin-like growth factor 1, prolactin, adre-
nocorticotropic hormone and cortisol.
DISCUSSION
IgG4-related disease was first proposed in relation to 
autoimmune pancreatitis (AIP) by Hamano and cols. 
in 2001 (4). Since then, it has been identified in virtu-
ally every tissue and is now considered a single condi-
tion that comprises multiple manifestations. Most pa-
tients are middle aged and elderly men and the disease 
usually presents subacutely, as a generalized entity or 
involving a single organ. Clinical findings are depen-
dent on the location of involved tissues and often in-
clude forming mass lesions, mimicking malignancies, 
Figure 2. (A, B, C) Cervical computed tomography images showing a 
thyroid gland with increased dimensions and a substernal component, 
producing a mass effect on the trachea.
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infections and other autoimmune-mediated disorders. 
Organ failure may occur. Fever, constitutional symp-
toms and elevation in laboratory inflammatory param-
eters are unusual (5-7).
Figure 3. Postoperative histopathological analysis of the thyroid gland. (A) Macroscopic findings revealing a large thyroid gland with a hard consistency. 
(B) An inflammatory infiltrate is seen, along with lymphoid follicles with germinal centers (black arrow) and marked fibrosis (hematoxylin and eosin, 40X). 
(C) Lymphoplasmacytic infiltration is found and atrophic follicles with oxyphilic cells predominate (hematoxylin and eosin, 200X). (D) Increased number of 
IgG4-positive plasma cells are seen, with > 50 cells per high-power field (IgG4 immunostaining, 400X).
Figure 4. Immunohistochemistry of IgG and IgG4. (A) Numerous IgG-positive plasma cells are found (IgG immunostaining, 400X). (B) An increased 
proportion of these cells are IgG4-positive, with an IgG4/IgG ratio of > 40% (IgG4 immunostaining, 400X).
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This condition is reported in the literature by dif-
ferent names: IgG4-related disease, IgG4-associated 
disease, IgG4-related systemic disease, IgG4-related 
sclerosing disease, IgG4-related systemic sclerosing 
disease, IgG4-related autoimmune disease, hyper-IgG4 
disease, IgG4-positive multiorgan lymphoproliferative 
syndrome, systemic IgG4-related plasmacytic syndrome 
and IgG4 syndrome. Some groups reached a consensus 
to refer it as IgG4-related disease (5,8).  
Diagnostic criteria have been proposed by some au-
thors (5,9), but are not universally established. They in-
clude, independently of the affected organ, histological 
features such as a dense lymphoplasmacytic infiltrate, 
storiform-type fibrosis and obliterative phlebitis, along 
with the demonstration of an increased population of 
IgG4-positive plasma cells. Cheuk and Chan consid-
ered that the diagnosis requires an increase in the ab-
solute number of IgG4-positive cells of > 50 per HPF 
and a raised IgG4-positive/IgG-positive ratio of > 40% 
(10). At least three HPFs should be used to calculate 
the average results. Deshpande and cols. stated that 
histological data are the mainstay for diagnosis, since 
both elevated numbers of IgG4-positive plasma cells 
and IgG4/IgG ratios have been described in other in-
flammatory conditions and malignancies (11). A high 
serum IgG4 concentration is often present but approxi-
mately 20-30% of patients with classic histopathological 
and immunochemical findings of the disease have nor-
mal serum levels (12). Therefore, it is not mandatory 
for the diagnosis of IgG4-related conditions. 
A preoperative suspicion is of greater significance 
because these patients can be treated with glucocor-
ticoids with the avoidance of surgery. Although they 
usually respond well to steroids, relapse can occur fol-
lowing therapy reduction or withdrawal. Some groups 
suggested therapeutic regimens (13). A major determi-
nant of treatment effectiveness is the degree of fibrosis 
and patients in whom fibrosis is well established are less 
likely to respond to glucocorticoids (7).
Our patient seems to have a single involvement 
of the thyroid gland and he presented with the clas-
sic diagnostic features of IgG4-related disease, namely: 
lymphoplasmacytic infiltrate, fibrosis and an increased 
number of IgG4-positive plasma cells.
Despite striking histopathological similarities among 
involved organ, subtle tissue variations are noticed (8). 
Organ-specific diagnostic criteria have been suggested 
for some of the IgG4-related conditions, but little is 
known about the thyroid gland. 
Patients with IgG4-related disease that included 
AIP have hypothyroidism in 27% of cases (14) and that 
finding led investigators to search for a relationship be-
tween HT and that systemic disease.
In 2009, Li and cols. first described a unique sub-
type of HT, known as IgG4-related HT, which was 
referred by those authors as IgG4 thyroiditis. They 
classified HT cases in two groups, IgG4 thyroiditis and 
non-IgG4 thyroiditis, based on IgG4 immunohisto-
chemistry, using the cut-off > 20 cells per HPF and 
> 30% IgG4/IgG ratio. The IgG4 thyroiditis group 
presented with severe lymphoplasmacytic infiltration, 
dense fibrosis, marked follicular cell degeneration, oxy-
philic change and lymphoid follicle formation, resem-
bling IgG4-related disease, and a relationship with this 
systemic entity was proposed (3). The same group in 
2010 demonstrated that the IgG4 thyroiditis group was 
associated with male gender, rapid progress requiring 
surgery, more subclinical hypothyroidism, higher levels 
of thyroid autoantibodies and more diffuse low echo-
genicity on US, when compared with the non-IgG4 
thyroiditis group (15). In 2012 these authors studied 
105 patients with HT and, using the same cut-off, 28 
cases (27%) were classified as IgG4 thyroiditis (16).
Our patient shows all the typical characteristics of 
IgG4-related HT. The presentation form, with neck 
swelling of rapid growing in a male patient, subclinical 
hypothyroidism, high levels of thyroid autoantibodies 
and low echogenicity on US, suggested the diagnosis, 
which was confirmed based on histological data and 
immunohistochemistry of IgG and IgG4. Since this 
condition seems to be more common than previously 
thought, we suggest performing the immunostaining 
in a case presenting with these typical clinical features 
and with lymphoplasmacytic infiltration and marked fi-
brosis.
When a preoperative suspicion of IgG4-related HT 
is present, glucocorticoid therapy may improve local 
symptoms and clinical outcomes. If the initial com-
plaints recur despite steroid therapy, surgical treat-
ment is required (17). However, as these patients usu-
ally present with a rapidly progressing neck swelling, 
surgery is often the first choice for treatment. Before 
surgical intervention serum IgG4 is often elevated but, 
after total thyroidectomy, levels usually exhibit a sig-
nificant reduction and return to normal, indicating that 
the major origin of IgG4 is the thyroid gland (16). In 
our case, serum IgG4 was not performed preoperative-
ly but a normal level one month after total thyroidec-
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tomy may suggest that it is decreasing and no other 
organ is involved besides the thyroid gland. The patient 
is asymptomatic, has normal laboratory inflammatory 
parameters and his thyroid function is controlled with 
levothyroxine.
IgG4-related HT also shares some features with the 
fibrous variant of HT, which accounts for 10-13% of 
HT cases. Its diagnostic criteria were defined by Katz 
and Vickery in 1974 and included a marked fibrous re-
placement of more than one-third of the thyroid pa-
renchyma and changes typical of HT in the remaining 
tissue (18). However, these conditions do not overlap 
completely. Li and cols. identified 14% of patients in 
the IgG4 thyroiditis group as having only mild fibrosis 
in the stroma, whereas 38% in the non-IgG4 thyroiditis 
group were found to meet the diagnostic criteria for 
the fibrous variant of HT. Some authors found that the 
IgG4 thyroiditis group was significantly associated with 
the presence of a predominant interfollicular pattern of 
fibrosis, while the fibrosis in the non-IgG4 thyroiditis 
group was mainly interlobular (19). 
In addition to IgG4-related HT, IgG4-related dis-
ease of the thyroid gland may include Riedel’s thyroid-
itis (RT), but this is still to be confirmed (15,20). RT 
is a rare condition, first recognized in 1896 by Bern-
hard Riedel (21). At the Mayo Clinic, 37 cases of RT 
were diagnosed in a series of 56,700 thyroidectomies 
performed between 1920 and 1984, giving an inci-
dence of 0.06% (22). The diagnostic criteria of this 
entity were established by Woolner and cols. in 1957, 
based on histological data (23). They have been modi-
fied and include: a fibroinflammatory process involving 
all or a portion of the thyroid gland, the presence of 
fibrous extension beyond the thyroid capsule into ad-
jacent anatomic structures, infiltration of inflammatory 
cells without giant cells, lymphoid follicles, oncocytes 
or granulomas, evidence of occlusive phlebitis and ab-
sence of a neoplasm (24).
Some characteristics can help distinguishing IgG4-
related HT and RT. The absence of extensive fibrosis 
beyond the thyroid capsule is still the most reliable 
evidence to confirm a diagnosis of IgG4-related HT. 
Furthermore, when IgG4-related disease occurs in a 
systemic pattern, the thyroid involvement may present 
as RT, since IgG4-related HT is organ-specific. In fact, 
none of the patients in the IgG4 thyroiditis group re-
ported by Li and cols. showed involvement of other 
organs (19). Therefore, in a patient with confirmed 
IgG4-related HT and no additional signs and symp-
toms, we consider that it is not mandatory to discard 
general IgG4-related disease. In addition, obliterative 
phlebitis is not present in any subtype of HT (16,24). 
Based on these features, our case is better defined as 
IgG4-related HT than as RT.
A relatively rapid growth in size of the thyroid gland 
should also lead to include lymphoma and other types 
of thyroid cancer in the differential diagnosis. Preexist-
ing HT is a risk factor for primary thyroid lymphoma 
(25).
Besides the thyroid gland, other endocrine organs 
can be involved in the spectrum of IgG4-related disease 
including the pituitary gland. More than 20 cases of 
IgG4-related hypophysitis have been described, all but 
one with pituitary insufficiency (26).
In conclusion, we report the first case of IgG4-related 
HT in a non-Asian patient, a Portuguese male present-
ing with a neck swelling of rapid growing and dysphagia, 
subclinical hypothyroidism, high levels of thyroid auto-
antibodies and low echogenicity on US. The presenta-
tion form and the additional histological data with lym-
phoplasmacytic infiltration and marked fibrosis were in 
agreement with the previous articles about IgG4-related 
HT, and led us to perform immunostaining for IgG 
and IgG4. The diagnosis was then confirmed. Our case 
highlights this new variant of the well known HT, and 
helps physicians in recognizing its main clinical features, 
allowing for proper diagnosis and treatment. 
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